Would you like to make a difference for severely burned patients in Europe?
COST Action CA23140 unites leading experts across Europe to improve burn care, in particular advanced therapy medicinal product (ATMPs) for burn patients. As a policymaker, your voice is essential in shaping the future of burn care across Europe. COST Action CA23140 brings together leading experts to advance innovative treatments, standardise care, and improve outcomes for burn patients.
The Action will engage in direct dialogues with policymakers and regulatory bodies. By presenting our research findings and recommendations, the Action aims to influence policy decisions that facilitate the adoption of ATMPs in burn care.
Why it matters?
- To stimulate a bottom-up approach for the development of ATMPs, and placing Europe as center of excellence for regenerative therapies for burns
- To empower young talents and train the next generation of leaders in the field by promoting intersectoral exchange between academic institutions and other stakeholders, facilitating the translation of innovative ATMPs from bench to bedside as market-ready therapies.
- To reduce the burden on healthcare systems by supporting more effective and cost-efficient management of severe burn cases.
- To bridge regulatory gaps and lift barriers in order to lead to advancements in ATMP approvals and accessibility, increasing patient access to innovative treatments while reducing administrative barriers for healthcare providers
This topic is being worked on in different COST ACTION Working Groups. For further details on this specific topic, please contact Céline Auxenfans directly (Celine.auxenfans@chu-lyon.fr) or use the contact options here.